E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
2018 · npj Breast Cancer · 87 citations
https://doi.org/10.1038/s41523-017-0053-3
A
Amyé Tevaarwerk
Mayo Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
233
Papers
4.4K
Citations
34
h-index
67
i10-index
Amyé Tevaarwerk is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer survivorship and care & Cancer Treatment and Pharmacology & Palliative Care and End-of-Life Issues. The author has an h-index of 34, co-authored 199 publications.
ORCID: 0000-0002-8087-5119Papers by this author
worksPhase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016 · Clinical Cancer Research · 51 citations
https://doi.org/10.1158/1078-0432.ccr-15-2365
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity
2011 · Breast Cancer Research and Treatment · 17 citations
https://doi.org/10.1007/s10549-011-1862-y
NCCN Guidelines® Insights: Survivorship, Version 2.2024
2024 · Journal of the National Comprehensive Cancer Network · 17 citations
https://doi.org/10.6004/jnccn.2024.0062
Lidocaine patches for postcesarean pain control in obese women: a pilot randomized controlled trial
2020 · American Journal of Obstetrics & Gynecology MFM · 12 citations
https://doi.org/10.1016/j.ajogmf.2020.100281
Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2–targeted therapy
2018 · Cancer · 1 citations
https://doi.org/10.1002/cncr.31878
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat